Jazz Pharmaceuticals Plc Shs U (JAZZ) Holder Timpani Capital Management Boosted Its Stake by $754,488 as Share Price Declined; First Midwest Bank Trust Division Holds Holding in Akorn (AKRX)

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Logo

Timpani Capital Management Llc increased its stake in Jazz Pharmaceuticals Plc Shs U (JAZZ) by 27.96% based on its latest 2018Q3 regulatory filing with the SEC. Timpani Capital Management Llc bought 4,491 shares as the company’s stock declined 15.85% with the market. The institutional investor held 20,552 shares of the major pharmaceuticals company at the end of 2018Q3, valued at $3.46M, up from 16,061 at the end of the previous reported quarter. Timpani Capital Management Llc who had been investing in Jazz Pharmaceuticals Plc Shs U for a number of months, seems to be bullish on the $7.55 billion market cap company. The stock increased 0.01% or $0.01 during the last trading session, reaching $125.08. About 548,297 shares traded. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has risen 3.57% since February 10, 2018 and is uptrending. It has outperformed by 3.57% the S&P500. Some Historical JAZZ News: 08/05/2018 – Jazz Pharmaceuticals Sees 2018 Adj EPS $12.75-Adj EPS $13.25; 24/04/2018 – BI UK: Frustrated investors want rare disease drugmaker Jazz to sell its blockbuster sleep business; 31/05/2018 – New Survey Highlights Lack of Awareness of Neurologic Effects Related to Excessive Sleepiness in Patients with Obstructive Slee; 08/05/2018 – Jazz Pharmaceuticals 1Q EPS 75c; 31/05/2018 – New Survey Highlights Lack of Awareness of Neurologic Effects Related to Excessive Sleepiness in Patients with Obstructive Sleep Apnea; 22/05/2018 – Jazz Pharma Presenting at UBS Conference Tomorrow; 08/05/2018 – Jazz Pharmaceuticals Sees 2018 Rev $1.88B-$1.93B; 10/05/2018 – Jazz Pharmaceuticals to Highlight Breadth of Research in Narcolepsy and Excessive Sleepiness in Obstructive Sleep Apnea at SLEE; 25/05/2018 – Jazz Pharma Presenting at Conference Jun 5; 08/05/2018 – JAZZ PHARMA SEES FY ADJ EPS $12.75 TO $13.25, EST. $12.82

First Midwest Bank Trust Division increased its stake in Akorn Inc (AKRX) by 203.68% based on its latest 2018Q3 regulatory filing with the SEC. First Midwest Bank Trust Division bought 89,237 shares as the company’s stock declined 68.17% with the market. The institutional investor held 133,049 shares of the health care company at the end of 2018Q3, valued at $1.73M, up from 43,812 at the end of the previous reported quarter. First Midwest Bank Trust Division who had been investing in Akorn Inc for a number of months, seems to be bullish on the $519.54M market cap company. The stock decreased 3.94% or $0.17 during the last trading session, reaching $4.14. About 1.23 million shares traded. Akorn, Inc. (NASDAQ:AKRX) has declined 86.27% since February 10, 2018 and is downtrending. It has underperformed by 86.27% the S&P500. Some Historical AKRX News: 03/05/2018 – FRESENIUS SE FREG.DE SAYS DOES NOT WANT TO SPECULATE ABOUT DURATION OF LAW SUITS, BUT EXPECTS TO RESOLVE AKORN ISSUE IN 2019; 23/04/2018 – STAT Plus: Pharmalittle: Fresenius walks away from Akorn deal; FDA bounces a Pfizer biosimilar; 09/03/2018 – Pomerantz Law Firm Announces the Filing of a Class Action against Akorn, Inc. and Certain Officers — AKRX; 27/03/2018 – Fresenius spokesman says probe into target Akorn continues; 11/05/2018 – S&P REVISES AKORN, INC. TO RATING ‘B’ FROM ‘B+’; 18/05/2018 – FRESENIUS CEO SEES AKORN CASE RESOLVED BY NEXT YEAR; 22/04/2018 – $AKRX Fresenius terminates merger agreement with Akorn due to Akorn’s failure to fulfill several closing conditions, including material breaches of FDA data integrity requirements; 27/03/2018 – FRESENIUS SE FREG.DE SPOKESMAN SAYS PROBE INTO AKORN CONTINUES; 02/04/2018 – The Klein Law Firm Announces a Class Action Filed on Behalf of Akorn, Inc. Shareholders and a Lead Plaintiff Deadline of May 7,; 23/04/2018 – SENVEST’S MASHAAL STILL SEES SIGNIFICANT DOWNSIDE FOR AKORN

First Midwest Bank Trust Division, which manages about $743.62 million US Long portfolio, decreased its stake in Western Digital Corp (NASDAQ:WDC) by 8,221 shares to 10,417 shares, valued at $610,000 in 2018Q3, according to the filing. It also reduced its holding in Ishares Tr (IVE) by 6,358 shares in the quarter, leaving it with 2,225 shares, and cut its stake in Select Sector Spdr Tr (XLE).

More notable recent Akorn, Inc. (NASDAQ:AKRX) news were published by: Globenewswire.com which released: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Akorn, Inc. (AKRX) – GlobeNewswire” on January 31, 2019, also Globenewswire.com with their article: “Akorn Announces New Executive and Board Appointments – GlobeNewswire” published on January 28, 2019, Businesswire.com published: “EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Akorn, Inc. – AKRX – Business Wire” on January 30, 2019. More interesting news about Akorn, Inc. (NASDAQ:AKRX) were released by: Seekingalpha.com and their article: “Akorn, chief operating officer part ways – Seeking Alpha” published on January 07, 2019 as well as Nasdaq.com‘s news article titled: “Akorn (AKRX) Gets FDA Warning Letter for Illinois Facility – Nasdaq” with publication date: January 10, 2019.

Among 18 analysts covering Akorn Inc (NASDAQ:AKRX), 6 have Buy rating, 2 Sell and 10 Hold. Therefore 33% are positive. Akorn Inc had 44 analyst reports since July 21, 2015 according to SRatingsIntel. RBC Capital Markets maintained Akorn, Inc. (NASDAQ:AKRX) on Monday, October 2 with “Hold” rating. As per Tuesday, August 29, the company rating was maintained by Piper Jaffray. The firm has “Hold” rating given on Friday, May 26 by Jefferies. The rating was maintained by RBC Capital Markets on Friday, September 1 with “Hold”. Leerink Swann maintained the stock with “Market Perform” rating in Wednesday, March 23 report. The rating was maintained by Jefferies on Tuesday, September 5 with “Hold”. The firm has “Market Perform” rating given on Wednesday, September 9 by JMP Securities. The stock has “Buy” rating by Nomura on Wednesday, December 2. The company was maintained on Tuesday, November 27 by Piper Jaffray. The rating was downgraded by Raymond James on Tuesday, August 2 to “Market Perform”.

Timpani Capital Management Llc, which manages about $202.98M and $347.07 million US Long portfolio, decreased its stake in Tabula Rasa Healthcare Inc by 18,000 shares to 63,471 shares, valued at $5.15M in 2018Q3, according to the filing. It also reduced its holding in Mimecast Limited by 71,965 shares in the quarter, leaving it with 40,790 shares, and cut its stake in Axogen Inc (NASDAQ:AXGN).

More notable recent Jazz Pharmaceuticals plc (NASDAQ:JAZZ) news were published by: Nasdaq.com which released: “Jazz (JAZZ) Falls as Sleep Drug Gets Extended Review From FDA – Nasdaq” on December 24, 2018, also Nasdaq.com with their article: “Is Jazz Pharmaceuticals a Great Stock for Value Investors? – Nasdaq” published on September 20, 2018, Nasdaq.com published: “TowerJazz Announces Smallest in the World Global Shutter Pixel Ramping to Production on 65nm Platform in its 300mm Japanese Site – Nasdaq” on January 28, 2019. More interesting news about Jazz Pharmaceuticals plc (NASDAQ:JAZZ) were released by: Nasdaq.com and their article: “Jazz Sells Pain Drug Prialt’s Rights to TerSera Therapeutics – Nasdaq” published on July 02, 2018 as well as Wallstreetpr.com‘s news article titled: “3 Biotech Stocks to Watch: QBioMed Inc, Seattle Genetics and Jazz Pharmaceuticals – WallStreetPR” with publication date: January 24, 2019.

Among 25 analysts covering Jazz Pharmaceuticals (NASDAQ:JAZZ), 20 have Buy rating, 0 Sell and 5 Hold. Therefore 80% are positive. Jazz Pharmaceuticals had 92 analyst reports since August 3, 2015 according to SRatingsIntel. The stock has “Buy” rating by Mizuho on Tuesday, February 21. BMO Capital Markets maintained Jazz Pharmaceuticals plc (NASDAQ:JAZZ) rating on Tuesday, October 24. BMO Capital Markets has “Buy” rating and $196.0 target. The stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) earned “Market Perform” rating by Bernstein on Wednesday, November 25. The stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has “Buy” rating given on Friday, March 16 by Leerink Swann. The firm has “Buy” rating by Cantor Fitzgerald given on Monday, April 30. Stifel Nicolaus maintained Jazz Pharmaceuticals plc (NASDAQ:JAZZ) rating on Wednesday, August 8. Stifel Nicolaus has “Buy” rating and $205 target. As per Thursday, July 27, the company rating was maintained by Cantor Fitzgerald. The stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has “Buy” rating given on Monday, August 7 by RBC Capital Markets. The firm earned “Buy” rating on Wednesday, February 28 by Cantor Fitzgerald. On Friday, September 22 the stock rating was maintained by Cowen & Co with “Buy”.

Akorn, Inc. (NASDAQ:AKRX) Institutional Positions Chart